|
|
Phase IV Randomized Study of Filgrastim (G-CSF) or Pegfilgrastim as Secondary Prophylaxis Versus Conservative Management of Chemotherapy-Induced Neutropenia for Maintenance of Chemotherapy in Women With Early Breast Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Supportive care
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
ACCOG-SCTN-BR0101 SCTN-BR0101, EU-20143, NCT00030758
|
|
|
Objectives - Determine the efficacy of filgrastim (G-CSF) or pegfilgrastim as secondary prophylaxis versus standard management after the first neutropenic event in maintaining dose-intensity of adjuvant chemotherapy in patients with early breast cancer.
- Determine the proportion of patients who experience at least one neutropenic event.
Entry Criteria Disease Characteristics:
- Histologically confirmed invasive breast cancer
- No locally advanced or metastatic breast cancer,
including supraclavicular fossa metastases
- Prior neutropenic event on current chemotherapy regimen, defined as 1 of the following:
- Hospitalization due to neutropenia
- Absolute neutrophil count ≤ 1.5 times upper limit of normal and considered sufficiently low to require a treatment delay or a dose reduction > 15% of planned dose
- Hormone receptor status:
Prior/Concurrent Therapy:
Biologic therapy: - No prior filgrastim (G-CSF) or pegfilgrastim
Chemotherapy: - See Disease Characteristics
- No prior chemotherapy other than current regimen
Endocrine therapy: Radiotherapy: - Concurrent radiotherapy allowed
- No concurrent sandwich/synchronous radiotherapy (i.e.,
administered during a break in the chemotherapy regimen)
Surgery: - See Disease Characteristics
Other: - Concurrent enrollment on other licensed chemotherapy trials
allowed provided G-CSF is not excluded (e.g., TACT or TANGO trials)
- Concurrent enrollment in the sequential arm of the SECRAB
trial allowed (synchronous arm ineligible)
Patient Characteristics:
Age: Sex: Menopausal status: Performance status: Life expectancy: Hematopoietic: - See Disease Characteristics
Hepatic: Renal: Other: - No other concurrent malignancy
- Considered suitable risk and fitness status to continue
adjuvant chemotherapy
Expected Enrollment 816A total of 400 patients will be accrued for this study
within 7 years. Outcomes Primary Outcome(s)Proportion of patients achieving ≥ 85% of planned dose intensity Proportion of patients with ≥ 1 neutropenic event
Secondary Outcome(s)Dose intensity achieved Cost of management
Outline This is a randomized, multicenter study. Patients are stratified
according to age (60 and under vs over 60) and participating center. Patients receive chemotherapy as per local practice. After the
first neutropenic event, patients are randomized to 1 of 2 treatment
arms. - Arm I: Patients receive filgrastim (G-CSF) subcutaneously (SC)
for 7 days beginning 2 days after the final dose in a course of adjuvant chemotherapy (e.g., beginning on day 3 for a course of chemotherapy administered on day 1 only OR beginning on day 10 for a course of chemotherapy administered on days 1 and 8) OR a single dose of pegfilgrastim SC administered approximately 24 hours after chemotherapy that is administered on day 1 only.
- Arm II: Patients receive standard conservative management.
Patients are followed for up to 10 years.
Trial Contact Information
Trial Lead Organizations Anglo Celtic Cooperative Oncology Group | | | Robert Leonard, MD, BS, MB, Protocol chair | | | |
Scottish Cancer Therapy Network | | | Kirsten Murray, Protocol chair | | | |
Registry Information | | Official Title | | G-CSF (filgrastim) or Pegfilgrastim Secondary Prophylaxis In The Adjuvant Chemotherapy Of Early Breast Cancer | | Trial Start Date | | 2001-10-03 | | Registered in ClinicalTrials.gov | | NCT00030758 | | Date Submitted to PDQ | | 2001-12-11 | | Information Last Verified | | 2007-06-25 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|